## Designing & Evaluating Clinical Algorithms for STI Case Management

Francis J. Ndowa WHO RHR/STI







### Session outline

- STI case management
- STI syndromic case management
- Algorithms development
- Implementation
- Algorithms evaluation
- Exercise (Group + presentation)







## Objectives of an STI programme

- to interrupt the transmission of sexually transmitted infections
- to prevent development of disease, complications and sequelae
- to reduce the risk of HIV infection







## Objectives of STI case management

- to provide appropriate antimicrobial therapy in order to:
  - obtain cure of infection
  - decrease infectiousness
- to limit or prevent high risk behaviour
- to ensure that sexual partners are treated in order to interrupt the chain of transmission







## STI case management: Requirements

- Accurate diagnosis
- Treat at first encounter
- Rapid cure with effective drugs
- Simplicity

- Integrated approach
- Condom promotion
- Education/Counselling
- Partner notification







# Comprehensive STI case management

- History taking and symptoms
- Examination
- Treatment
  - Client and partner(s)








# Factors that influence patients' choice of facility

- Accessibility
  - proximity
  - affordability
- Acceptability
  - non-stigmatising
  - non-judgmental staff attitudes
  - convenient opening hours
  - affordable fees

- Quality of services
  - efficiency of service delivery
  - competence of staff
  - effectiveness of therapy
  - availability of drugs





## Diagnostic approaches to STI

clinical

laboratory

syndromic

#### **Disadvantages**

- neither sensitive nor specific
- mixed infections cannot be detected
- simple tests not available/do not exist
- cost: existing rapid test expensive
- delay: results not readily available
- costs of over-treatment
- side-effects of over-treatment







## STI syndromic case management: definition

 Syndromic diagnosis: identification of consistent group of symptoms and easily recognised signs (syndromes)

Syndromic treatment: treat the main organisms responsible for causing the syndrome







## How syndromic management works

### Through a series of flow-charts:


- guides the health-care worker through the correct identification and treatment of an STI-associated syndrome
- offers a package of comprehensive care from history taking, examination, to counselling/education on risk reduction and partner notification







### **Urethral Discharge**




World Health Organization

Reproductive Health and Research

UNDP . UNFPA . WHO . World Bank Special Programme of Research, Development and Research Training in Human Reproduction


### **Urethral discharge (with microscope)**







#### **Genital ulcers**











# Agents causing genital ulcer disease (GUD) by Region until 1990's








### Proportion of genital ulcers in which HSV-2 was isolated in Africa over time



Mayaud & Mc Cormick, Br Med Bull 2001

and Research Training in Human Reproduction

# Aetiology of GUS by M-PCR and culture in Masaka, Uganda



TPHA/RPR - 15% HIV - 30%




Source: Dr. Anatoli Kamali, Uganda







UNDP • UNFPA • WHO • World Bank Special Programme of Research, Development and Research Training in Human Reproduction



\*In 1993 a study was done by the National AIDS Control Program in Botswana in collaboration with the STD Research Unit, South

African Institute for Medical Research, Johannesburg among 108 GUD patients.


Source: M. Rahman, ISSTDR, Ottawa 2003







### Botswana Aetiology of genital ulcer disease 2002




TPHA/RPR - 15% HIV - 30%

Source: M. Rahman, ISSTDR, Ottawa 2003










### Current genital ulcer algorithm in Botswana




World Health Organization


Reproductive Health and Research

ЯR




### Piloted genital ulcer algorithm in Botswana





## Prevalence of Selected STIs among Female Populations in Africa in the 1980's and 1990's



## Vaginal discharge syndrome

### **VAGINITIS**

- most common causes
- easy to diagnose
  - lab tests
  - clinically
- serious complications?
  - // (pregnancy)
  - (endometritis, PID)

### **CERVICITIS**


- less common causes
- not easy to diagnose
  - no simple tests
- complications ++
  - PID
  - ectopic pregnancy
  - infertility








### Vaginal discharge (with speculum only)



World Health Organization

Reproductive Health and Research

Special Programme of Research, Development and Research Training in Human Reproduction











# Vaginal discharge (without microscope, using risk score)























## 1. Pre-requisite information

- Prevalence of STIs
- STI treatment-seeking behaviour
- Treatment practices & counselling (PI6 & PI7)
- Level of (and capacity for) training of implementers
- Drug policy, ordering and distribution system
- Stakeholders involvement
- Review of literature (need 'evidence criteria')








## 2. Conduct or analyse aetiological studies

- Genital ulcer syndrome
- Male genital discharge syndrome
- Female genital discharge (+/- risk-assessment)
- Resistance patterns
- 3. Assess if there is need to depart from WHO or existing national/regional algorithms
- 4. Adaptation for high/low risk environment
  - high/low prevalence area
  - high risk/low risk populations







### 5. Determine the role of the laboratory

- for case management (and monitoring as 'test of cure')
- for screening and case finding
- for supporting research

## 6. Determine levels of use/capacity

- will influence flowchart design & need pre-testing
- will influence choice of drugs
- depends on referral patterns







# 7. Drug selection: criteria for the choice of drugs (WHO, 2003)

- efficacy (cure at least 95% of those infected)
- safety
- cost
- compliance and acceptability
- -availability (e.g. at primary health care level)
- use in pregnancy
- broad spectrum (can cover co-existing infections)
- resistance unlikely to occur rapidly

- 8. Printing and distribution (and translation) of flowcharts
- 9. Training
  - post-service institutional training
  - on-the-job training
  - pre-service training
  - what cadres to train
- 10. Drug procurement and distribution







### 11. Monitoring and Supervision

- WHAT?
  - clinical outcomes on returnees and non-returnees
    - » cured/ improved/ treatment failures
    - » referral/ no follow-up
  - Neisseria gonorrhoeae susceptibility
  - aetiological surveys
  - quality of care (PI6, PI7)
- HOW (universal? sentinel sites? standardised protocols? consensual workshops)
- WHEN?


#### 12. Evaluation scheme







## Monitoring & Evaluation



Special Programme of Research, Development and Research Training in Human Reproduction

## **Evaluation of Algorithms**

- Validity: sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV)
- Feasibility: infrastructure, personnel
- Cost: direct and indirect costs, cost/effectiveness
- Acceptability: health care provider, STI patient, programme manager

## Validity of an algorithm (1):

### Comparison between:

- Outcome of the algorithm
  - -Simulation studies
  - Real outcome in field conditions

- Gold standard diagnosis
  - Laboratory tests







## Validity of an algorithm (2)

- Calculation: 2 x 2 table
  - sens, spec, PPV, NPV

- Interpretation: 2 x 2 table
  - correctly treated, over treated, missed infections







## Validity of an algorithm Interpretation

**Gold Standard test** 

٠

**Algorithm** 

A: (true +ve)
Correctly treated

B: (false ve+)
Over-treated

-

C: (false -ve)

D: (true -ve)

Missed infections

Correctly diagnosed as negative

**Total infected** 

**Total not infected** 







## Validity of an algorithm Interpretation

#### **Gold Standard test**

**Algorithm** 

+	A: (true +ve)	B: (false ve+)
-	C: (false -ve)	D: (true -ve)
7	Total infected	Total non infected

Sensitivity: A/A+C

Specificity: D/B+D

Positive Predictive Value: A/A+B
Negative Predictive Value: D/C+D


















UNDP • UNFPA • WHO • World Bank Special Programme of Research, Development and Research Training in Human Reproduction